{"disease":{"id":"epidermal-nevus-syndrome","name":"epidermal nevus syndrome"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02304367","title":"Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Kyowa Kirin, Inc.","has_results":true},{"nct_id":"NCT04320316","title":"A Trial to Assess the Safety and Efficacy of KRN23 in Epidermal Nevus Syndrome (ENS)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}